Clinical trials

  • BEMARITUZUMAB for FGFR2b-positive advanced or metastatic gastric adenocarcinoma | FGFR2b-positive advanced or metastatic gastroesophageal junction adenocarcinoma
  • NECVAX-NEO1 for Triple-negative breast cancer
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Pancreatic ductal adenocarcinoma | Pancreatic adenocarcinoma
  • BBO-8520 for Non-small cell lung cancer
  • Lutetium-177 DOTA-TATE for Somatostatin receptor-positive tumours
  • BUPRENORPHINE for Major depressive episode | Clinical depression | Suicidal ideation
  • Vinblastine sulfate; Cisplatin for Early triple-negative breast cancer (TNBC)
  • ALANINE, ARGININE, DEFEROXAMINE, HISTIDINE, ASPARTIC ACID, GLYCINE, TRYPTOPHAN, SUCROSE, CALCIUM, MAGNESIUM, POTASSIUM, SODIUM, N-HYDROXY-3,4-DIMETHOXY-N-METHYL-BENZAMIDE, N-ACETYLHISTIDINE, CHLORIDE ION, OXOGLURIC ACID for Kidney transplantation | Liver transplantation | Kidney–pancreas transplantation
  • COBAMAMIDE, LEVOCARNITINE for Septic shock | Acute kidney injury
  • PATRITUMAB DERUXTECAN for Colorectal carcinoma | Biliary tract carcinoma | Hepatocellular carcinoma
  • BI 1831169 for Solid tumors
  • DURVALUMAB for Non-small cell lung cancer